StreetInsider.com News Articles

Mesa Labs to cut 40 jobs, target $5M net cost reduction

Tue, 13 Oct 2026 08:02:47 -0400

Mesa Laboratories, Inc. (NASDAQ: MLAB) announced a savings plan intended to reduce annualized operating costs by approximately $9.3 million, with plans to reinvest approximately $4.3 million of those savings, resulting in a net annualized cost reduction of approximately $5.0 million.

The Lakewood, Colorado-based company said the plan includes a global restructuring program, a reduction in its San Diego, California facility footprint, and cuts to third-party spending. As part of the restructuring, Mesa will eliminate approximately 40 positions, representing about 6% of its total workforce, with limited impact on manufacturing operations.

Cost reductions are concentrated primarily in the Clinical Genomics division, with additional

Mesa Labs to cut 40 jobs, target $5M net cost reduction

Tue, 13 Oct 2026 08:02:47 -0400

Cost reductions are concentrated primarily in the Clinical Genomics division, with additional

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth

Tue, 13 Oct 2026 08:00:00 -0400

The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia

LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million. The Savings Plan consists of a global restructuring program (the "Restructuring Program"), a reduction in our San Diego, California facility footprint and reduced third-party spending.

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth

Tue, 13 Oct 2026 08:00:00 -0400

The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia

Form 8-K MESA LABORATORIES INC For: Oct 12

Tue, 13 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261013/27177419.html

Mesa Laboratories (MLAB) Declares $0.16 Quarterly Dividend; 0.5% Yield

Fri, 09 Oct 2026 16:00:01 -0400

Mesa Laboratories (NASDAQ: MLAB) declared a quarterly dividend of $0.16 per share, or $0.64 annualized.

The dividend will be payable on December 15, 2026, to stockholders of record on November 30, 2026, with an ex-dividend date of November 27, 2026.

The annual yield on the dividend is 0.5 percent.

For a dividend history and other dividend-related data on Mesa Laboratories (MLAB) click here.

MESA LABS DECLARES QUARTERLY DIVIDEND

Fri, 09 Oct 2026 16:00:00 -0400

Lakewood, Colo., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2026, to shareholders of record at the close of business on November 30, 2026.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of critical quality control solutions and life science tools for regulated applications in the pharmaceutical, healthcare and

MESA LABS DECLARES QUARTERLY DIVIDEND

Fri, 09 Oct 2026 16:00:00 -0400

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of critical quality control solutions and life science tools for regulated applications in the pharmaceutical, healthcare and

Form SCHEDULE 13G MESA LABORATORIES INC Filed by: WASATCH ADVISORS LP

Fri, 09 Oct 2026 15:47:00 -0400

si-local-file:///var/storage/secattach/20261009/27171386.html

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400